News
CAPR
5.86
-6.24%
-0.39
Weekly Report: what happened at CAPR last week (0408-0412)?
Weekly Report · 1d ago
Weekly Report: what happened at CAPR last week (0401-0405)?
Weekly Report · 04/08 12:13
Solid Biosciences gets FDA rare pediatric disease status for DMD therapy
Healthcare Solid Biosciences gets FDA rare pediatric disease status for DMD therapy. SGT-003 for the treatment of Duchenne muscular dystrophy. The company expects the first patient in a Phase 1/2 study for the therapy to be dosed in Q2.
Seeking Alpha · 04/01 14:17
Weekly Report: what happened at CAPR last week (0325-0329)?
Weekly Report · 04/01 12:09
Weekly Report: what happened at CAPR last week (0318-0322)?
Weekly Report · 03/25 12:13
Canopy Growth, Capricor Therapeutics, GT Biopharma among healthcare movers
Healthcare On the Move: Canopy Growth, Capricor Therapeutics, GT Biopharma among healthcare movers. S&P 500 Health Care Sector +0.23% to 1703.09. Pharmaceuticals, Biotechnology & Life Science contributes 58% to index.
Seeking Alpha · 03/22 14:00
Weekly Report: what happened at CAPR last week (0311-0315)?
Weekly Report · 03/18 12:11
Catalyst announces US launch of Duchenne drug Agamree
Healthcare Catalyst announces US launch of Duchenne drug Agamree in the U.S. For the treatment of muscular dystrophy. The therapy was approved by the FDA in October. Other drugmakers with DMD therapies in development or on the market include Roche and Pfizer.
Seeking Alpha · 03/13 17:46
Capricor Therapeutics, Inc. Is Worried About This – Should You Be Worried Too?
TipRanks · 03/12 06:01
Weekly Report: what happened at CAPR last week (0304-0308)?
Weekly Report · 03/11 12:06
Can Capricor (CAPR) Climb 261.27% to Reach the Level Wall Street Analysts Expect?
NASDAQ · 03/07 14:55
Capricor Therapeutics: Strong Buy Rating Backed by Robust Financials and Promising Clinical Progress
TipRanks · 03/05 17:55
Regenxbio stock jumps 13% on positive data for DMD drug
Regenxbio stock jumps 13% on positive data for DMD drug. The company reported positive data from a Phase 1/2 study of its drug RGX-202 in the treatment of Duchenne muscular dystrophy. Other companies developing treatments for the disease include Sarepta and Capricor.
Seeking Alpha · 03/05 16:03
Weekly Report: what happened at CAPR last week (0226-0301)?
Weekly Report · 03/04 12:09
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Keros Therapeutics (KROS), Veeva Systems (VEEV) and Capricor Therapeutics (CAPR)
TipRanks · 03/01 11:20
Capricor Therapeutics Inc: Current report
Press release · 02/29 23:54
Capricor Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Capricor Therapeutics Inc reports results for the quarter ended in December. Revenue rose 1,159.2% to $12.09 million from a year ago. The company reported a quarterly adjusted loss of 2 cents per share. The mean expectation of three analysts was for a loss of 9 cents.
Reuters · 02/29 23:31
Press Release: Capricor Therapeutics Reports -2-
Carrying the muscle-targeting moiety were not detected in any other tissues. Capricor announced completion of a registered direct offering with Nippon Shinyaku for gross proceeds of approximately $23.0 million. The Company's cash, cash equivalents and marketable securities totaled approximately $39.5 million as of December 31, 2023. The company expects to complete development of CAP-1002 for Duchenne Muscular Dystrophy in 2024.
Dow Jones · 02/29 21:05
Capricor Therapeutics Q4 2023 Earnings Preview
Capricor Therapeutics (NASDAQ:CAPR) is scheduled to announce Q4 earnings on Thursday, February 29th. The consensus EPS estimate is -$0.09 and the consensus Revenue Estimate is $10.6M. Over the last 1 year, CAPR has beaten EPS estimates 75% of the time.
Seeking Alpha · 02/28 22:35
Capricor Therapeutics's Earnings Outlook
Capricor Therapeutics is set to give its latest quarterly earnings report on Thursday, 2024-02-29. The company is expected to report an earnings per share of $-0.09. Last quarter the company beat EPS by $0.04. Shares of CapricorTherapeutics were trading at $4.34 as of February 27.
Benzinga · 02/28 17:01
More
Webull provides a variety of real-time CAPR stock news. You can receive the latest news about Capricor Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About CAPR
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. The Company leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases.